<DOC>
	<DOCNO>NCT00242528</DOCNO>
	<brief_summary>To evaluate safety tolerability intravenous zoledronic acid treatment patient multiple myeloma stage III bone lesion related Cancer .</brief_summary>
	<brief_title>Open-label Study , Evaluate Safety Tolerability Zoledronic Acid Patients With Bone Lesions Secondary Multiple Myeloma .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Confirmed Diagnosis DurieSalmon Stage III Multiple Myeloma , follow clinical characteristic : A . At least 1 osteolytic bone lesion demonstrable conventional Xray film . B . The patient receive treatment primary neoplasia , time start trial . Ambulatory patient age ≥ 18 year . Treatment bisphosphonates moment last 12 month visit 1. except patient receive one dosis bisphosphonates indication administration 14 day old . Patients absence bone lesion clearly related primary cancer , detectable conventional bone Xray ( simple film ) . Patients Serum Calcium level ≤ 8 g/dl ( 2.00 mmol/L ) ≥ 12 mg/dL ( 3.00 mmol/L ) Treatment investigational drug within 30 day inclusion trial . Serum Creatinine level &gt; 3 mg/dl ( 265 umol/L ) . Total Billirubin level &gt; 2.5 mg/dl ( 43 umol/L ) Patients heart condition NYHA criterion Grade III IV functional class Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Bone Lesions</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>zoledronic acid</keyword>
</DOC>